← 홈

다발성 골수종

229개 · ADC 1032 · Antibody 4683 · CGT 2713 · 다음 갱신 D-8 · 마지막 7월 21일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 229개
AntibodystaleIndapta Therapeutics, INC.Phase 3

Isatuximab (Isatuximab)

NHL; Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase3#인기#항체+5
효능 ORR 67%임상시험 56상태 RECRUITING
ADCBiologicstaleFortis Therapeutics, Inc.Phase 2

FOR46 (FOR46)

Multiple Myeloma; Multiple Myeloma in Relapse · Prostate Cancer Metastatic

#ProstateCancerMetastatic#ADC#Phase2#인기#항체약물접합체+4
효능 ORR 51.5%임상시험 55상태 RECRUITING
CGTBiologicstaleCarbiogene Therapeutics Co. Ltd.Phase 1

anti-BCMA CAR-T (anti-BCMA CAR-T)

Multiple Myeloma · BCMA

#BCMA#CGT#Phase1#인기#세포유전치료+5
효능 ORR 97.1%임상시험 55상태 ACTIVE
AntibodystalePfizerApproved

Elranatamab (Elranatamab)

Multiple Myeloma · FRα

#FR#Antibody#Approved#인기#항체+5
효능 ORR 61%임상시험 54상태 RECRUITING
CGTBiologicInternational Brain Research Fo…Phase 2

Quercetin (Quercetin)

Recurrent Multiple Myeloma; Refractory Multiple Myeloma · FRα

#FR#CGT#Phase2#인기#세포유전치료+5
임상시험 54상태 RECRUITING
AntibodystaleRegeneronPhase 2

Cemiplimab REGN2810 (Cemiplimab REGN2810)

Plasma Cell Myeloma · Prostate Cancer

#ProstateCancer#Antibody#Phase2#인기#항체+5
효능 ORR 55.6%임상시험 51상태 ACTIVE
AntibodystalePfizerPhase 2

PF-06863135 (Elranatamab, Elranatamab (PF-06863135))

Multiple Myeloma · FRα

#FR#Antibody#Phase2#인기#항체+5
효능 ORR 61%임상시험 51상태 ACTIVE
ADCBiologicstalePfizerPhase 3

Iberdomide (Iberdomide)

Multiple Myeloma · FRα

#FR#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 92.9%임상시험 47상태 RECRUITING
CGTBiologicPoseida Therapeutics, Inc.Phase 2

autologous anti-BCMA chimeric antigen receptor T cells (autologous anti-BCMA chimeric antigen receptor T cells)

ITP · BCMA

#BCMA#CGT#Phase2#세포유전치료#CAR-T+4
효능 ORR 97.1%임상시험 47상태 ACTIVE
CGTBiologicMerck Sharp & Dohme LLCPhase 2

Letermovir (Letermovir)

Relapsed Refractory Multiple Myeloma (RRMM) · Cell Therapy

#CellTherapy#CGT#Phase2#세포유전치료#CAR-T+4
임상시험 45상태 RECRUITING
AntibodystaleJack Khouri, MDPhase 2

Siltuximab (Siltuximab)

Multiple Myeloma; Cytokine Release Syndrome · Myelofibrosis

#Myelofibrosis#Antibody#Phase2#항체#면역항체+5
효능 ORR 46.7%임상시험 43상태 RECRUITING
AntibodystaleJanssenPhase 3

Talquetamab (Talquetamab)

Myeloma Multiple; Plasma Cell Leukemia · FRα

#FR#Antibody#Phase3#항체#면역항체+5
임상시험 40상태 DISCONTINUED
CGTBiologicstaleSung-Soo ParkPreclinical

IMiD treatment (IMiD treatment)

Multiple Myeloma, Relapsed; Multiple Myeloma (MM) · FRα

#FR#CGT#Preclinical#세포유전치료#CAR-T+5
효능 ORR 48.3%임상시험 39상태 RECRUITING
AntibodySanofiPhase 3

Isatuximab SAR650984 (Isatuximab SAR650984)

Immune System Disorder · Plasma Cell Myeloma

#PlasmaCellMyeloma#Antibody#Phase3#항체#면역항체+4
효능 ORR 55.6%임상시험 39상태 ACTIVE
ADCBiologicstaleSanofiPhase 2

Belumosudil (Belumosudil)

Plasma Cell Myeloma Refractory · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 74%임상시험 38상태 RECRUITING
CGTBiologicBristol-Myers SquibbPhase 2

bb2121 (Ide-cel, Ide-cel (bb2121))

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#CGT#Phase2#세포유전치료#CAR-T+3
효능 ORR 74.5%임상시험 33상태 RECRUITING
CGTBiologicBeijing BiotechPhase 2

AP1903 (AP1903)

Leukemia; Myeloma · Sarcoma

#Sarcoma#CGT#Phase2#세포유전치료#CAR-T+5
효능 ORR 2%임상시험 32상태 RECRUITING
ADCBiologicstaleJanssen Research & Development,…Phase 2

Nirogacestat (Nirogacestat)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 57%임상시험 32상태 RECRUITING
CGTBiologicstaleChinese PLA General HospitalPhase 2

Anti-BCMA-CD19 CAR-T cells (Anti-BCMA-CD19 CAR-T cells)

IgG4 Related Disease; B-cell Mediated Autoimmune Disorders · CD19

#CD19#CGT#Phase2#세포유전치료#CAR-T+5
임상시험 30상태 RECRUITING
AntibodystaleGilead SciencesPhase 2

Magrolimab (Magrolimab)

Solid Tumor; Colorectal Cancer · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase2#항체#면역항체+4
효능 ORR 66.7%임상시험 30상태 DISCONTINUED

2 / 12 페이지

← 이전다음 →